Value of low dose combination treatment with blood pressure lowering drugs
Clinical & Experimental Cardiology

Clinical & Experimental Cardiology
Open Access

ISSN: 2155-9880

Value of low dose combination treatment with blood pressure lowering drugs

4th International Conference on Clinical & Experimental Cardiology

April 14-16, 2014 Hilton San Antonio Airport, TX, USA

Malcolm Law

Accepted Abstracts: J Clin Exp Cardiolog

Abstract :

Systematic review of evidence from randomised controlled trials of blood pressure lowering drugs and from cohort studies shows that a blood pressure reduction of 10mmHg systolic/5mmhg diastolic reduces risk of CHD events by an estimated 25% and stroke by 36%. These risk reductions are attributable to blood pressure lowering; the drugs have no major pleiotropic effects. The proportional risk reductions are similar in primary and secondary prevention, and apply irrespective of the level of pre-treatment blood pressure (down to 110/70). The 5 major classes of blood pressure lowering drugs reduce blood pressure and risk of CVD events to a similar extent, but using the drugs in low-dose combinations minimises adverse effects: 3 drugs together in half dose cause side effects in an estimated 5% of people only, and reduce risk of CHD by 46% and stroke by 62%. Blood pressure guidelines need to move away from the traditional ?hypertensive/normotensive? concept; the decision to take drugs to lower blood pressure lowering drugs should be based on overall cardiovascular risk, not level of blood pressure.